Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Revolution Medicines (RVMD) Accumulated Depreciation & Amortization (2018 - 2025)

Revolution Medicines (RVMD) has 7 years of Accumulated Depreciation & Amortization data on record, last reported at $27.0 million in Q3 2025.

  • For Q3 2025, Accumulated Depreciation & Amortization rose 24.64% year-over-year to $27.0 million; the TTM value through Sep 2025 reached $27.0 million, up 24.64%, while the annual FY2024 figure was $21.8 million, 336.46% up from the prior year.
  • Accumulated Depreciation & Amortization reached $27.0 million in Q3 2025 per RVMD's latest filing, up from $21.8 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $27.0 million in Q3 2025 and bottomed at $700000.0 in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $9.4 million, with a median of $4.0 million recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: plummeted 56.52% in 2022, then surged 1769.89% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $3.1 million in 2021, then grew by 29.03% to $4.0 million in 2022, then grew by 25.0% to $5.0 million in 2023, then surged by 336.46% to $21.8 million in 2024, then rose by 23.79% to $27.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $27.0 million in Q3 2025, $21.8 million in Q4 2024, and $21.7 million in Q3 2024.